Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06056063 · ClinicalTrials.gov registry record · NA

Project Looking-Glass Evaluation

A NA study of Cone-Beam Computed Tomography, sponsored by Abramson Cancer Center at Penn Medicine.

Active
Registry status
NA
Development phase
27
Enrollment target
1
Study location

NCT06056063: Active NA study of Cone-Beam Computed Tomography, sponsored by Abramson Cancer Center at Penn Medicine.

NCT06056063 is a NA study of Cone-Beam Computed Tomography that is active but no longer recruiting, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 27 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06056063, a NA study of Cone-Beam Computed Tomography, is active but no longer recruiting, sponsored by Abramson Cancer Center at Penn Medicine.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
27 participants
Enrollment target
1
Study location

Study Summary

Pilot study to validate the new design and workflow of Cone-Beam CT imaging for radiation therapy treatment simulation.

Primary Outcome

Qualitative results (Yes is acceptable/No is not acceptable) will be reported as tabulated data to demonstrate the differences from the standard practice

Interventions

  • DEVICE Halcyon 4.0

Study Locations (1)

Pennsylvania

  • Perelman Center for Advanced Medicine - Philadelphia

Trial Details

FieldValue
Enrollment Target 27 participants
Start Date 2023-11-19
Est. Completion 2026-09-30
Phase NA

What the registry record for NCT06056063 still lists

NCT06056063 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Cone-Beam Computed Tomography appearing as the primary indexed condition, and to 1 intervention - of which Halcyon 4.0 is the first listed.

NCT06056063 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT06056063 about?

NCT06056063 is a clinical study titled "Project Looking-Glass Evaluation". Pilot study to validate the new design and workflow of Cone-Beam CT imaging for radiation therapy treatment simulation.

What is the current status of trial NCT06056063?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 27 participants. The study started on 2023-11-19. Estimated completion is 2026-09-30.

What conditions does trial NCT06056063 study?

This clinical trial studies the following conditions: Cone-Beam Computed Tomography.

What interventions are being tested in trial NCT06056063?

The interventions under investigation include: Halcyon 4.0 (DEVICE).

Who is sponsoring clinical trial NCT06056063?

This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06056063 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

How this trial's enrollment target compares

Where NCT06056063's enrollment target sits among peer trials

27 1708th of 2000 higher than 291 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00912041 · 27 participants · NA

    BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia

  • NCT02847559 · 27 participants · Phase 2

    Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma

  • NCT03380195 · 27 participants · NA

    Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness

  • NCT03384238 · 27 participants · Phase 1

    Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06056063, the US trial registry maintained by the National Library of Medicine. NCT06056063 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.